Redeye: Bioinvent - Partner agreements the key to unlocking the case

The Bioinvent stock has underperformed the broader market during 2019 (-35%), mainly due to the rights issue earlier this year. We believe much negative already is priced in the share, and see a risk/reward skewed towards the upside.

Läs mer och ladda ned analysen av Klas Palin: http://bit.ly/2V7fip2

Bli medlem hos Redeye för att få tillgång till de senaste analyserna och uppdateringarna.

Detta är ett pressmeddelande från Redeye - Research Powered Investment Banking. https://www.redeye.se/about